Colorectal cancer

Evelien Dekker, Pieter J. Tanis, Jasper L.A. Vleugels, Pashtoon M. Kasi, Michael B. Wallace

Research output: Contribution to journalReview article

Abstract

Several decades ago, colorectal cancer was infrequently diagnosed. Nowadays, it is the world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing population and dietary habits of high-income countries, unfavourable risk factors such as obesity, lack of physical exercise, and smoking increase the risk of colorectal cancer. Advancements in pathophysiological understanding have increased the array of treatment options for local and advanced disease leading to individual treatment plans. Treatments include endoscopic and surgical local excision, downstaging preoperative radiotherapy and systemic therapy, extensive surgery for locoregional and metastatic disease, local ablative therapies for metastases, and palliative chemotherapy, targeted therapy, and immunotherapy. Although these new treatment options have doubled overall survival for advanced disease to 3 years, survival is still best for those with non-metastasised disease. As the disease only becomes symptomatic at an advanced stage, worldwide organised screening programmes are being implemented, which aim to increase early detection and reduce morbidity and mortality from colorectal cancer.

Original languageEnglish (US)
Pages (from-to)1467-1480
Number of pages14
JournalThe Lancet
Volume394
Issue number10207
DOIs
StatePublished - Oct 19 2019

Fingerprint

Colorectal Neoplasms
Therapeutics
Feeding Behavior
Palliative Care
Immunotherapy
Radiotherapy
Obesity
Smoking
Exercise
Neoplasm Metastasis
Morbidity
Drug Therapy
Mortality
Population
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., & Wallace, M. B. (2019). Colorectal cancer. The Lancet, 394(10207), 1467-1480. https://doi.org/10.1016/S0140-6736(19)32319-0

Colorectal cancer. / Dekker, Evelien; Tanis, Pieter J.; Vleugels, Jasper L.A.; Kasi, Pashtoon M.; Wallace, Michael B.

In: The Lancet, Vol. 394, No. 10207, 19.10.2019, p. 1467-1480.

Research output: Contribution to journalReview article

Dekker, E, Tanis, PJ, Vleugels, JLA, Kasi, PM & Wallace, MB 2019, 'Colorectal cancer', The Lancet, vol. 394, no. 10207, pp. 1467-1480. https://doi.org/10.1016/S0140-6736(19)32319-0
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. The Lancet. 2019 Oct 19;394(10207):1467-1480. https://doi.org/10.1016/S0140-6736(19)32319-0
Dekker, Evelien ; Tanis, Pieter J. ; Vleugels, Jasper L.A. ; Kasi, Pashtoon M. ; Wallace, Michael B. / Colorectal cancer. In: The Lancet. 2019 ; Vol. 394, No. 10207. pp. 1467-1480.
@article{4206adcef2ca4257afe4c0317580e443,
title = "Colorectal cancer",
abstract = "Several decades ago, colorectal cancer was infrequently diagnosed. Nowadays, it is the world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing population and dietary habits of high-income countries, unfavourable risk factors such as obesity, lack of physical exercise, and smoking increase the risk of colorectal cancer. Advancements in pathophysiological understanding have increased the array of treatment options for local and advanced disease leading to individual treatment plans. Treatments include endoscopic and surgical local excision, downstaging preoperative radiotherapy and systemic therapy, extensive surgery for locoregional and metastatic disease, local ablative therapies for metastases, and palliative chemotherapy, targeted therapy, and immunotherapy. Although these new treatment options have doubled overall survival for advanced disease to 3 years, survival is still best for those with non-metastasised disease. As the disease only becomes symptomatic at an advanced stage, worldwide organised screening programmes are being implemented, which aim to increase early detection and reduce morbidity and mortality from colorectal cancer.",
author = "Evelien Dekker and Tanis, {Pieter J.} and Vleugels, {Jasper L.A.} and Kasi, {Pashtoon M.} and Wallace, {Michael B.}",
year = "2019",
month = "10",
day = "19",
doi = "10.1016/S0140-6736(19)32319-0",
language = "English (US)",
volume = "394",
pages = "1467--1480",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10207",

}

TY - JOUR

T1 - Colorectal cancer

AU - Dekker, Evelien

AU - Tanis, Pieter J.

AU - Vleugels, Jasper L.A.

AU - Kasi, Pashtoon M.

AU - Wallace, Michael B.

PY - 2019/10/19

Y1 - 2019/10/19

N2 - Several decades ago, colorectal cancer was infrequently diagnosed. Nowadays, it is the world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing population and dietary habits of high-income countries, unfavourable risk factors such as obesity, lack of physical exercise, and smoking increase the risk of colorectal cancer. Advancements in pathophysiological understanding have increased the array of treatment options for local and advanced disease leading to individual treatment plans. Treatments include endoscopic and surgical local excision, downstaging preoperative radiotherapy and systemic therapy, extensive surgery for locoregional and metastatic disease, local ablative therapies for metastases, and palliative chemotherapy, targeted therapy, and immunotherapy. Although these new treatment options have doubled overall survival for advanced disease to 3 years, survival is still best for those with non-metastasised disease. As the disease only becomes symptomatic at an advanced stage, worldwide organised screening programmes are being implemented, which aim to increase early detection and reduce morbidity and mortality from colorectal cancer.

AB - Several decades ago, colorectal cancer was infrequently diagnosed. Nowadays, it is the world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing population and dietary habits of high-income countries, unfavourable risk factors such as obesity, lack of physical exercise, and smoking increase the risk of colorectal cancer. Advancements in pathophysiological understanding have increased the array of treatment options for local and advanced disease leading to individual treatment plans. Treatments include endoscopic and surgical local excision, downstaging preoperative radiotherapy and systemic therapy, extensive surgery for locoregional and metastatic disease, local ablative therapies for metastases, and palliative chemotherapy, targeted therapy, and immunotherapy. Although these new treatment options have doubled overall survival for advanced disease to 3 years, survival is still best for those with non-metastasised disease. As the disease only becomes symptomatic at an advanced stage, worldwide organised screening programmes are being implemented, which aim to increase early detection and reduce morbidity and mortality from colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=85073506559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073506559&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(19)32319-0

DO - 10.1016/S0140-6736(19)32319-0

M3 - Review article

C2 - 31631858

AN - SCOPUS:85073506559

VL - 394

SP - 1467

EP - 1480

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10207

ER -